Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons. // The Lancet Infectious Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S1473309926002859?dgcid=rss_sd_all
Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons. The Lancet Infectious Diseases. https://www.sciencedirect.com/science/article/pii/S1473309926002859?dgcid=rss_sd_all
“Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons.” The Lancet Infectious Diseases.
@article{article101640,
title = {Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons},
journal = {The Lancet Infectious Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S1473309926002859?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...